These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 34856980)

  • 21. Is pentraxin 3 a new cardiovascular risk marker in polycystic ovary syndrome?
    Sari U; Kaygusuz I; Kafali H
    Gynecol Obstet Invest; 2014; 78(3):173-8. PubMed ID: 25011417
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The independent effects of polycystic ovary syndrome and obesity on serum concentrations of gonadotrophins and sex steroids in premenopausal women.
    Holte J; Bergh T; Gennarelli G; Wide L
    Clin Endocrinol (Oxf); 1994 Oct; 41(4):473-81. PubMed ID: 7955458
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Atherogenic metabolic profile in PCOS patients: role of obesity and hyperandrogenism.
    Castelo-Branco C; Steinvarcel F; Osorio A; Ros C; Balasch J
    Gynecol Endocrinol; 2010 Oct; 26(10):736-42. PubMed ID: 20569105
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Serum levels of inhibins are differentially altered in patients with polycystic ovary syndrome: effects of being overweight and relevance to hyperandrogenism.
    Pigny P; Cortet-Rudelli C; Decanter C; Deroubaix D; Soudan B; Duhamel A; Dewailly D
    Fertil Steril; 2000 May; 73(5):972-7. PubMed ID: 10785223
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The impact of polycystic ovary syndrome and body mass index on the absorption of recombinant human follicle stimulating hormone.
    Lee MS; Lanes A; Dolinko AV; Bailin A; Ginsburg E
    J Assist Reprod Genet; 2020 Sep; 37(9):2293-2304. PubMed ID: 32623663
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Elevated circulating levels of secreted frizzled-related protein 4 in relation to insulin resistance and androgens in women with polycystic ovary syndrome.
    Bicer M; Alarslan P; Guler A; Demir I; Aslanipour B; Calan M
    J Endocrinol Invest; 2020 Mar; 43(3):305-313. PubMed ID: 31486991
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The comparative effectiveness of 55 interventions in obese patients with polycystic ovary syndrome: A network meta-analysis of 101 randomized trials.
    Abdel-Maboud M; Menshawy A; Hasabo EA; Abdelraoof MI; Alshandidy M; Eid M; Menshawy E; Outani O; Menshawy A
    PLoS One; 2021; 16(7):e0254412. PubMed ID: 34280195
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clinical and metabolic characteristics of Turkish adolescents with polycystic ovary syndrome.
    Ates S; Aydın S; Ozcan P; Soyman Z; Gokmen Karasu AF; Sevket O
    J Obstet Gynaecol; 2018 Feb; 38(2):236-240. PubMed ID: 28920502
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The phenotypic diversity in per-follicle anti-Müllerian hormone production in polycystic ovary syndrome.
    Alebić MŠ; Stojanović N; Duhamel A; Dewailly D
    Hum Reprod; 2015 Aug; 30(8):1927-33. PubMed ID: 26048913
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Plasma visfatin levels in normal weight women with polycystic ovary syndrome.
    Panidis D; Farmakiotis D; Rousso D; Katsikis I; Delkos D; Piouka A; Gerou S; Diamanti-Kandarakis E
    Eur J Intern Med; 2008 Oct; 19(6):406-12. PubMed ID: 18848173
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Reproductive and metabolic determinants of granulosa cell dysfunction in normal-weight women with polycystic ovary syndrome.
    Guedikian AA; Lee AY; Grogan TR; Abbott DH; Largaespada K; Chazenbalk GD; Dumesic DA
    Fertil Steril; 2018 Mar; 109(3):508-515. PubMed ID: 29428312
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effects of metformin therapy on hyperandrogenism in women with polycystic ovarian syndrome.
    Kazerooni T; Dehghan-Kooshkghazi M
    Gynecol Endocrinol; 2003 Feb; 17(1):51-6. PubMed ID: 12724019
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Anti-Müllerian Hormone in Pathogenesis, Diagnostic and Treatment of PCOS.
    Rudnicka E; Kunicki M; Calik-Ksepka A; Suchta K; Duszewska A; Smolarczyk K; Smolarczyk R
    Int J Mol Sci; 2021 Nov; 22(22):. PubMed ID: 34830389
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Ovarian morphology assessed by magnetic resonance imaging in women with and without polycystic ovary syndrome and associations with antimüllerian hormone, free testosterone, and glucose disposal rate.
    Leonhardt H; Hellström M; Gull B; Lind AK; Nilsson L; Janson PO; Stener-Victorin E
    Fertil Steril; 2014 Jun; 101(6):1747-56.e1-3. PubMed ID: 24661732
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparison of clinical and hormonal characteristics among four phenotypes of polycystic ovary syndrome based on the Rotterdam criteria.
    Jamil AS; Alalaf SK; Al-Tawil NG; Al-Shawaf T
    Arch Gynecol Obstet; 2016 Feb; 293(2):447-56. PubMed ID: 26408006
    [TBL] [Abstract][Full Text] [Related]  

  • 36. CAG repeat polymorphism in androgen receptor gene is not directly associated with polycystic ovary syndrome but influences serum testosterone levels.
    Skrgatic L; Baldani DP; Cerne JZ; Ferk P; Gersak K
    J Steroid Biochem Mol Biol; 2012 Feb; 128(3-5):107-12. PubMed ID: 22107839
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Efficacy of electroacupuncture in regulating the imbalance of AMH and FSH to improve follicle development and hyperandrogenism in PCOS rats.
    Shi Y; Li L; Zhou J; Sun J; Chen L; Zhao J; Wu L; Cui Y; Wu L; Wu H
    Biomed Pharmacother; 2019 May; 113():108687. PubMed ID: 30851546
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Menstrual dysfunction in polycystic ovary syndrome: association with dynamic state insulin resistance rather than hyperandrogenism.
    Ezeh U; Ezeh C; Pisarska MD; Azziz R
    Fertil Steril; 2021 Jun; 115(6):1557-1568. PubMed ID: 33602559
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Chronic inflammation and elevated homocysteine levels are associated with increased body mass index in women with polycystic ovary syndrome.
    Guzelmeric K; Alkan N; Pirimoglu M; Unal O; Turan C
    Gynecol Endocrinol; 2007 Sep; 23(9):505-10. PubMed ID: 17852421
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cardiovascular disease risk characteristics of the main polycystic ovary syndrome phenotypes.
    Dilbaz B; Ozkaya E; Cinar M; Cakir E; Dilbaz S
    Endocrine; 2011 Jun; 39(3):272-7. PubMed ID: 21547513
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.